AVITA Medical, Inc.
RCEL, AVHHL · Surgical & Medical Instruments & Apparatus · 30.8M shares · +6%/yr ↑ dilution · EDGAR filings ↗
Reference price $4.00 · est. market cap ~$123M — last insider purchase, 2026-06-09 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D42Medical-device company (the RECELL skin-regeneration system) with operating losses and cash burn.
Strengths
- Liquidity — current ratio 0.57 (14th)
Risks
- Operating/net losses & cash burn — per metrics
- near-insolvent liquidity and negative equity amplify the burn — per 10-K
- Adoption/reimbursement dependence — per 10-K
Notable findings
- No interest coverageInterest coverage -8.50 (cannot cover interest)
- Net lossNet loss (net margin -67.8%)
- Cash burnNegative free cash flow (-32.2M)
- Weak liquidityCurrent ratio 0.57 (<1)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Insider buyingInsider buying — 13 open-market buy(s) by 2 insider(s) (cluster of 2 insiders, ~$226,640, last 6mo) Form 4 ↗
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, FMR LLC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
82.1%
Operating margin
-59.4%
Net margin
-67.8%
Return on equity
291.8%
Return on assets
-86.2%
Revenue growth (QoQ)
9.3%
Debt / equity
0.0×
Interest coverage
-8.5×
Current ratio
0.6×
Free cash flow
-$32M
EBITDA
-$40M
Tangible book value
-$22M
Cash & investments
$18M
Cash runway
2q
Stock comp / revenue
13.3%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-12 | O'Toole David D | Grant | 2.0K | $3.97 |
| 2026-06-09 | Woody Joseph Fralin | Buy | 5.2K | $4.00 |
| 2026-06-09 | Woody Joseph Fralin | Buy | 5.0K | $4.20 |
| 2026-06-09 | Woody Joseph Fralin | Buy | 5.0K | $4.18 |
| 2026-06-03 | Woody Joseph Fralin | Buy | 5.0K | $4.10 |
| 2026-06-03 | Woody Joseph Fralin | Buy | 5.0K | $4.09 |
| 2026-06-02 | Woody Joseph Fralin | Buy | 5.0K | $4.18 |
| 2026-06-02 | Woody Joseph Fralin | Buy | 5.0K | $4.21 |
| 2026-06-01 | Woody Joseph Fralin | Buy | 5.0K | $4.26 |
| 2026-06-01 | Woody Joseph Fralin | Buy | 5.0K | $4.34 |
| 2026-05-29 | Vance Cary Guy | Grant | 5.0K | $3.05 |
| 2026-05-29 | O'Toole David D | Grant | 5.0K | $3.05 |
| 2026-05-20 | O'Toole David D | Buy | 2.0K | $4.26 |
| 2026-05-19 | O'Toole David D | Buy | 2.0K | $4.24 |
| 2026-03-11 | O'Toole David D | Buy | 1.8K | $4.78 |
| 2026-02-19 | O'Toole David D | Buy | 3.0K | $4.15 |
| 2026-02-18 | O'Toole David D | Grant | 105K | — |
| 2026-02-18 | KELSEY NICOLE | Grant | 98K | — |
| 2026-01-20 | Woody Joseph Fralin | Grant | 22K | — |
| 2026-01-20 | COOK JEREMY CURNOCK | Grant | 22K | — |
| 2026-01-20 | Crowe Suzanne | Grant | 22K | — |
| 2026-01-20 | Tarnoff Michael E | Grant | 22K | — |
| 2026-01-20 | McNamara Robert | Grant | 22K | — |
| 2026-01-20 | REED JAN STERN | Grant | 22K | — |
| 2026-01-05 | Woody Joseph Fralin | Grant | 41K | — |
| 2025-08-28 | McNamara Robert | Buy | 10K | $4.50 |
| 2025-08-26 | O'Toole David D | Buy | 2.0K | $4.52 |
| 2025-08-19 | McNamara Robert | Buy | 10K | $5.00 |
| 2025-08-12 | O'Toole David D | Buy | 2.0K | $4.81 |
| 2025-08-06 | Tarnoff Michael E | Grant | 26K | — |
| 2025-05-30 | O'Toole David D | Grant | 1.9K | $4.78 |
| 2025-03-06 | McNamara Robert | Buy | 11K | $8.30 |
| 2025-02-20 | O'Toole David D | Buy | 1.0K | $9.90 |
| 2025-02-20 | McNamara Robert | Buy | 10K | $10.09 |
| 2025-02-19 | O'Toole David D | Buy | 1.0K | $10.25 |
| 2025-01-21 | Panaccio Lou | Grant | 10K | — |
| 2025-01-21 | Crowe Suzanne | Grant | 10K | — |
| 2025-01-21 | COOK JEREMY CURNOCK | Grant | 10K | — |
| 2025-01-21 | McNamara Robert | Grant | 10K | — |
| 2025-01-21 | REED JAN STERN | Grant | 10K | — |
| 2025-01-21 | Vance Cary Guy | Grant | 10K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT02380612 ↗ | ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries Burns | NA | Completed | 2016-01-21 |
| NCT01138917 ↗ | A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries Burns | NA | Completed | 2014-08-29 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-08 | Material agreementExhibits | filing ↗ |
| 2026-06-04 | Exec/director changeShareholder vote | filing ↗ |
| 2026-05-14 | ResultsExhibits | filing ↗ |
| 2026-05-01 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-02-12 | ResultsExhibits | filing ↗ |
| 2026-01-13 | Material agreement1.02ResultsDebt obligation3.02Exhibits | filing ↗ |
| 2026-01-05 | Exec/director changeExhibits | filing ↗ |
| 2025-11-06 | Material agreementResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-08 | 2026-06-05 | 0001762303-26-000011 ↗ |
| 8-K | 2026-06-04 | 2026-06-03 | 0001762303-26-000003 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001193125-26-224107 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001193125-26-224022 ↗ |
| 8-K | 2026-05-01 | 2026-04-30 | 0001193125-26-201662 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001193125-26-048761 ↗ |
| 10-K | 2026-02-12 | 2025-12-31 | 0001193125-26-049031 ↗ |
| 8-K | 2026-01-13 | 2026-01-13 | 0001193125-26-011167 ↗ |
| 8-K | 2026-01-05 | 2026-01-01 | 0001193125-26-002418 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001193125-25-269597 ↗ |
| 8-K | 2025-11-06 | 2025-11-05 | 0001193125-25-269535 ↗ |
| 8-K | 2025-10-17 | 2025-10-16 | 0001193125-25-241705 ↗ |